226 related articles for article (PubMed ID: 34104541)
1. T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival.
Christina Svensson M; Lindén A; Nygaard J; Borg D; Hedner C; Nodin B; Leandersson K; Jirström K
Oncoimmunology; 2021 May; 10(1):1921443. PubMed ID: 34104541
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8
Fukuoka E; Yamashita K; Tanaka T; Sawada R; Sugita Y; Arimoto A; Fujita M; Takiguchi G; Matsuda T; Oshikiri T; Nakamura T; Suzuki S; Kakeji Y
Anticancer Res; 2019 Aug; 39(8):4539-4548. PubMed ID: 31366557
[TBL] [Abstract][Full Text] [Related]
3. High Infiltration of CD68+/CD163- Macrophages Is an Adverse Prognostic Factor after Neoadjuvant Chemotherapy in Esophageal and Gastric Adenocarcinoma.
Svensson MC; Svensson M; Nodin B; Borg D; Hedner C; Hjalmarsson C; Leandersson K; Jirström K
J Innate Immun; 2022; 14(6):615-628. PubMed ID: 35504250
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
Chen S; Wang RX; Liu Y; Yang WT; Shao ZM
Int J Cancer; 2017 Mar; 140(6):1384-1395. PubMed ID: 27925176
[TBL] [Abstract][Full Text] [Related]
5. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
Kim HS; Kim JY; Lee YJ; Kim SH; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
Gynecol Oncol; 2018 Dec; 151(3):414-421. PubMed ID: 30314669
[TBL] [Abstract][Full Text] [Related]
6. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
Zhao J; Meisel J; Guo Y; Nahta R; Hsieh KL; Peng L; Wei Z; O'Regan R; Li X
Breast Cancer Res Treat; 2020 Oct; 183(3):599-606. PubMed ID: 32715443
[TBL] [Abstract][Full Text] [Related]
8. Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy.
Liang Y; Yu M; Zhou C; Zhu X
Diagn Pathol; 2020 Jun; 15(1):67. PubMed ID: 32493336
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression in breast invasive ductal carcinoma with incomplete pathological response to neoadjuvant chemotherapy.
Alhesa A; Awad H; Bloukh S; Al-Balas M; El-Sadoni M; Qattan D; Azab B; Saleh T
Int J Immunopathol Pharmacol; 2022; 36():3946320221078433. PubMed ID: 35225058
[TBL] [Abstract][Full Text] [Related]
10. Dynamic alteration and prognostic significance of tumor-associated CD68
Wu J; Xie RY; Wei LH; Cao CZ; Shang BQ; Guan YY; Shi HZ; Qu W; Li Y; Liang J; Zheng S; Zhou AP; Zhou XF; Shou JZ; Bi XG
Cancer Med; 2023 Feb; 12(4):4981-4992. PubMed ID: 36043478
[TBL] [Abstract][Full Text] [Related]
11. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
[TBL] [Abstract][Full Text] [Related]
12. The effect of neoadjuvant therapy on PD-L1 expression and CD8+lymphocyte density in non-small cell lung cancer.
Zens P; Bello C; Scherz A; von Gunten M; Ochsenbein A; Schmid RA; Berezowska S
Mod Pathol; 2022 Dec; 35(12):1848-1859. PubMed ID: 35915139
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
[TBL] [Abstract][Full Text] [Related]
14. Programmed death-1 ligands and tumor infiltrating T lymphocytes in primary and lymph node metastasis of esophageal cancer patients.
Konno-Kumagai T; Fujishima F; Nakamura Y; Nakano T; Nagai T; Kamei T; Sasano H
Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30085020
[TBL] [Abstract][Full Text] [Related]
15. The expression of C-MYC in gastric adenocarcinoma is associated with PD-L1 and FOXP3 expression: C-MYC overexpression is a good prognostic factor.
Won KY; Kim GY; Kim HK; Song MJ; Choi SI; Bae GE; Lim SJ
Pathol Res Pract; 2019 Nov; 215(11):152639. PubMed ID: 31582185
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of T cells, B cells and the PD-1/PD-L1 pathway in muscle invasive bladder cancer: a comparative study of transurethral resection and cystectomy specimens.
Wahlin S; Nodin B; Leandersson K; Boman K; Jirström K
Oncoimmunology; 2019; 8(11):e1644108. PubMed ID: 31646091
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy is linked to an amended anti-tumorigenic microenvironment in gastric cancer.
Huan X; Zou K; Zhang P; Ding H; Luo C; Xiang C; Xu S; Zhuang Y; Wu C; Wang Y; Wu X; Chen C; Zhang J; Yao X; Liu F; Liu S; Wu Z
Int Immunopharmacol; 2024 Jan; 127():111352. PubMed ID: 38091833
[TBL] [Abstract][Full Text] [Related]
18. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
[TBL] [Abstract][Full Text] [Related]
19. Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy.
Tsuchiya T; Someya M; Takada Y; Hasegawa T; Kitagawa M; Fukushima Y; Gocho T; Hori M; Nakata K; Hirohashi Y; Torigoe T; Saito T; Sakata KI
Strahlenther Onkol; 2020 Aug; 196(8):725-735. PubMed ID: 31953603
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
Koh J; Ock CY; Kim JW; Nam SK; Kwak Y; Yun S; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS
Oncotarget; 2017 Apr; 8(16):26356-26367. PubMed ID: 28412752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
